Aktienanalyse zu Grail Inc (GRAL)GRALGrail Inc

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer. It operates in the Healthcare sector (MEDICAL LABORATORIES industry).

Grail Inc (GRAL) is currently trading at $117.81, which is significantly below the average analyst price target of $150. However, the stock has seen a sharp decline of 16.20% over the last five days and has an RSI of 29.27, indicating it is oversold. The recent FDA support for its Galleri test has led to an 80% increase in stock price over the past month, suggesting potential for recovery. The main risk is the uncertainty surrounding insurance coverage for the Galleri test, which could impact profitability.